Rein Therapeutics Inc.
RNTXRein Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for orphan pulmonary and fibrosis indications with high unmet medical needs.
Earnings
Next report
Aug 13, 2026 (in a month)Financials
Q1 2026Competitors
By market cap
Profile
Rein Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for orphan pulmonary and fibrosis indications with high unmet medical needs. The company's core value proposition centers on its proprietary peptide and proenzyme platforms that target pro-fibrotic signaling and protect healthy lung epithelial cells. Currently, the firm is prioritizing the development of its lead candidate for Idiopathic Pulmonary Fibrosis while managing a pipeline of treatments for other respiratory conditions.
Rein Therapeutics is a specialized clinical-stage player focusing on unique Cav1-related peptide mechanisms that distinguish it from standard anti-fibrotic therapies.
Questions, answered.
- What is Rein Therapeutics Inc.'s market cap?
- Rein Therapeutics Inc. (RNTX) has a market capitalization of $85.4M and trades on NASDAQ.
- Who are Rein Therapeutics Inc.'s competitors?
- Rein Therapeutics Inc.'s key competitors include AbbVie Inc., Bristol Myers Squibb Company, Gilead Sciences, Inc., and others. These companies compete in similar markets and product categories.
- Who does Rein Therapeutics Inc. partner with?
- Rein Therapeutics Inc.'s notable partners include Taiho Pharmaceutical Co. Ltd., University of Texas Health Science Center at Tyler, University of Texas at Austin, and others.
- What subsidiaries does Rein Therapeutics Inc. have?
- Rein Therapeutics Inc.'s subsidiaries include Lung Therapeutics, Inc..
- Where is Rein Therapeutics Inc. headquartered?
- Rein Therapeutics Inc. is headquartered in United States of America and employs approximately 3 people. It has been publicly traded since 2017.